Company Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells.
The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer.
It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 2, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Daniel Passeri |
Contact Details
Address: 40 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617 949 2680 |
| Website | cuebiopharma.com |
Stock Details
| Ticker Symbol | CUE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645460 |
| CUSIP Number | 22978P106 |
| ISIN Number | US22978P1066 |
| Employer ID | 47-3324577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Passeri J.D., M.Sc. | Chief Executive Officer and Director |
| Kerri-Ann Millar CPA | Chief Financial Officer |
| Dr. Matteo Levisetti M.D. | Chief Medical Officer |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo J. Chaparro Ph.D. | Co-Founder |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| Colin G. Sandercock J.D., MSE | Senior Vice President, General Counsel and Secretary |
| Lucinda Warren | Chief Business Officer |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 424B5 | Filing |
| Apr 14, 2025 | 424B5 | Filing |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 14, 2025 | PRE 14A | Other preliminary proxy statements |